US/UK/Canada

Share

Pick a time period -
Tags ( Active)

BioStock: Sensidose is growing and sees opportunities in Finland

The pharmaceutical company Sensidose is growing and sees new opportunities in new markets. According to yesterday's year-end report, sales rose by 10.9 per cent in existing markets. At the same time, the company reported last week that the product Flexilev had been granted a subsidy in Finland. BioStock contacted CEO Jack Spira to learn more about new opportunities in Finland and continued market expansion.Read the interview with Sensidose's CEO Jack Spira at biostock.se: https://www.biostock.se/en/2023/02/sensidose-is-growing-and-sees-opportunities-in-finland/ This is a press release

Sensidose granted reimbursement for Flexilev in Finland

As part of Sensidose's ongoing geographical expansion, the company last autumn applied for reimbursement for Flexilev with the Finnish Pharmaceutical Price Board (Lääkkeiden hintalautakunta). The application has now been granted and the approval is in accordance with the reimbursement in the other Nordic countries."The positive reimbursement decision is an important step in our geographical market expansion. Now we look forward to getting started with sales as soon as possible and giving Finnish Parkinson's disease patients access to Flexilev, says Sensidose CEO Jack Spira. Flexilev is

BioStock: 100 days as Sensidose's Deputy CEO

The pharmaceutical company Sensidose has developed and markets a method for individualized treatment of Parkinson's disease in the advanced phase, the so-called wearing off phase or fluctuation phase. In November 2022, Philip Slätis took over as Deputy CEO and COO to accelerate the company’s business development and continued international expansion. 100 days into his new role as Sensidose's Deputy CEO, BioStock took the opportunity to feel Slätis' pulse and hear more about the company's growth plans.Read the interview with Sensidose's Deputy CEO at biostock.se: https://www.biostock.se/

BioStock: Sensidose expects sales growth despite drop in Q3

Spotlight-listed Sensidose reports progress in several areas in the third quarter, despite component shortages and other challenges. During the period, important steps were taken in the market expansion preparations, but also in the development of the new dose dispenser OraFID and the reprogramming of MyFID. In addition, Philip Slätis was recruited as COO and Deputy CEO. The company is now looking forward to the coming period with an expectation of sales growth and market expansion. BioStock contacted CEO Jack Spira to know more about the development.Read the interview with Sensidose's CEO

BioStock: Congress in Poland paves the way for Sensidose

Recently, Sensidose participated in the Polish Neurology Society’s annual science and education conference in Lublin. An increased presence is a strategic step ahead of the planned market launch of the company’s drug Flexilev for the treatment of Parkinson’s disease in Poland. The company’s CEO Jack Spira tells us more about the launch plans in Poland and the learnings from the congress.Read the whole article about Sensidose at biostock.se: https://www.biostock.se/en/2022/09/congress-in-poland-paves-the-way-for-sensidose/ Detta är ett pressmeddelande från BioStock – Connecting

BioStock: Sensidose’s founder talks about the company’s journey

The idea for Sensidose’s treatment strategy came about already in the mid-1990s when professors Sten-Magnus Aquilonius and Christer Nyström realized that it would be possible to personalise Parkinson’s treatment with microtablets. Today, the company’s drug Flexilev is available on the Scandinavian market and in the near future also in more countries. BioStock had a chat with Sten-Magnus Aquilonius about his research and Sensidose’s journey from start to now.Read the full article at biostock.se: https://www.biostock.se/en/2022/09/sensidoses-founder-talks-about-the-companys-journey/

BioStock: Sensidose recruits Deputy CEO for the expansion

Pharma company Sensidose has recruited Philip Slätis as Chief Operating Officer and Deputy CEO. Slätis takes on on his role on November 1 and brings broad experience from the pharmaceutical industry. He is expected to contribute to the company’s business development and continued expansion with Flexilev for individualized treatment of Parkinson’s disease in the advanced phase, the so-called wearing-off stage.Read the full article at biostock.se: https://www.biostock.se/en/2022/09/sensidose-recruits-deputy-ceo-for-the-expansion/ This is a press release from BioStock - Connecting

BioStock: Continued positive sales development for Sensidose

Sensidose recently reported an increase in net sales of 21 per cent for the second quarter compared to the same period in 2021. At the same time as the company is growing, they have also made progress during the quarter in the development of the new dosing device, which is expected to drive further growth and profitability in the coming years. The company is now looking forward to the coming months when several pieces of the puzzle are expected to fall into place, according to CEO Jack Spira.Read the full article at biostock.se: https://www.biostock.se/en/2022/08/continued-positive-sales-

BioStock: Sensidose’s CEO looks towards autumn after strong growth

Sensidose can greet the halfway point of 2022 with a strong cash position after its listing on Spotlight and rising sales despite a shortage of components. In addition, the company recently submitted an application for certification of the dosing apparatus MyFID under MDR, the new regulatory framework for medical devices. BioStock talked to CEO Jack Spira regarding the achievements of the first half of the year and the outlook for autumn.Read the full article at biostock.se: https://www.biostock.se/en/2022/07/sensidoses-ceo-looks-towards-autumn-after-strong-growth/ This is a press

BioStock: Rising sales for newly listed Sensidose

Sensidose, active in Parkinson’s disease, reports its best sales figures to date in the company's history. Compared to the same period last year, sales increased by as much as 27 per cent. In addition, the company's cash position was recently strengthened by approximately 21.5 million SEK in connection with the listing on Spotlight Stock Market, which means that the company is equipped for continued growth.Read the interview with Sensidose's CEO Jack Spira at biostock.se: https://www.biostock.se/en/2022/05/rising-sales-for-newly-listed-sensidose/ This is a press release from BioStock -

BioStock: Sensidose ready for expansion and IPO

Sensidose is a pharmaceutical company that sells a proprietary, non-invasive and personalized dosing system for Parkinson’s patients, who are towards the later phases of the disease. The company’s medicine and dosing system is currently marketed in Sweden, Norway and Denmark, and Sensidose aims to expand to more geographic markets. Furthermore Sensidose is developing its treatment system with a new dosing device aimed towards patients who are in an earlier stage of the disease. As Sensidose is preparing for an IPO in 2022, BioStock contacted CEO Jack Spira to find out more about the plans for

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe